Sun Pharma's research arm Sun Pharma Advanced Research Company (SPARC) and China's biotech firm HitGen Wednesday announced a collaboration to identify novel small molecule leads for targets of interest.
Under the terms of the agreement, HitGen will receive upfront payment and will be eligible for certain milestone payments.
"Under this collaboration, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads for SPARC," both companies said in a joint statement.
The statement, however, did not elaborate on details of the payments.
HitGen Chairman of the board and chief executive officer Jin Li said the company will work closely with SPARC scientists to generate novel leads for their innovative research programmes to address unmet medical needs.
HitGen is a biotech company with headquarters and main research facilities based in Chengdu, China, and a subsidiary in the USA.
Shares of SPARC were trading 2.08 per cent higher from its previous close at Rs 200.80 apiece on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app